Prothena Corporation PLC (PRTA) Expected to Post Q3 2017 Earnings of ($1.44) Per Share

Prothena Corporation PLC (NASDAQ:PRTA) – Equities researchers at Oppenheimer Holdings boosted their Q3 2017 earnings per share estimates for Prothena Corporation PLC in a research report issued on Wednesday. Oppenheimer Holdings analyst J. Olson now forecasts that the biotechnology company will earn ($1.44) per share for the quarter, up from their prior estimate of ($1.62). Oppenheimer Holdings has a “Outperform” rating and a $70.00 price target on the stock. Oppenheimer Holdings also issued estimates for Prothena Corporation PLC’s Q4 2017 earnings at ($1.64) EPS, FY2017 earnings at ($4.54) EPS, FY2018 earnings at ($4.79) EPS, FY2019 earnings at ($4.98) EPS, FY2020 earnings at ($1.81) EPS and FY2021 earnings at ($1.79) EPS.

Other analysts have also issued reports about the stock. ValuEngine lowered shares of Prothena Corporation PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 27th. Zacks Investment Research lowered shares of Prothena Corporation PLC from a “buy” rating to a “hold” rating in a research note on Monday, May 15th. Jefferies Group LLC began coverage on shares of Prothena Corporation PLC in a research note on Monday, July 10th. They issued a “buy” rating and a $100.00 price target for the company. BTIG Research began coverage on shares of Prothena Corporation PLC in a research note on Friday, May 19th. They issued a “buy” rating and a $80.00 price target for the company. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Prothena Corporation PLC in a research note on Tuesday, May 16th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Prothena Corporation PLC has a consensus rating of “Buy” and an average target price of $77.09.

TRADEMARK VIOLATION WARNING: This article was first posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://transcriptdaily.com/2017/08/13/prothena-corporation-plc-prta-expected-to-post-q3-2017-earnings-of-1-44-per-share.html.

Shares of Prothena Corporation PLC (NASDAQ PRTA) opened at 57.16 on Friday. The firm’s market cap is $2.19 billion. The company has a 50-day moving average of $60.52 and a 200-day moving average of $54.91. Prothena Corporation PLC has a 12 month low of $40.58 and a 12 month high of $69.53.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.43. The firm had revenue of $26.81 million during the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The firm’s revenue was up 7951.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.18) earnings per share.

A number of hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its stake in Prothena Corporation PLC by 1.2% in the first quarter. Principal Financial Group Inc. now owns 6,528 shares of the biotechnology company’s stock valued at $364,000 after buying an additional 77 shares in the last quarter. OMERS ADMINISTRATION Corp raised its stake in Prothena Corporation PLC by 2.0% in the second quarter. OMERS ADMINISTRATION Corp now owns 5,000 shares of the biotechnology company’s stock valued at $271,000 after buying an additional 100 shares in the last quarter. Bank of Montreal Can raised its stake in Prothena Corporation PLC by 6.7% in the second quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 117 shares in the last quarter. ProShare Advisors LLC raised its stake in Prothena Corporation PLC by 1.0% in the second quarter. ProShare Advisors LLC now owns 22,910 shares of the biotechnology company’s stock valued at $1,240,000 after buying an additional 216 shares in the last quarter. Finally, Nationwide Fund Advisors raised its stake in Prothena Corporation PLC by 0.9% in the second quarter. Nationwide Fund Advisors now owns 46,504 shares of the biotechnology company’s stock valued at $2,517,000 after buying an additional 407 shares in the last quarter.

In related news, Director Dennis J. Selkoe sold 3,500 shares of the stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $58.11, for a total transaction of $203,385.00. Following the completion of the sale, the director now directly owns 6,345 shares of the company’s stock, valued at $368,707.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $64.89, for a total transaction of $324,450.00. Following the sale, the insider now directly owns 5,000 shares of the company’s stock, valued at $324,450. The disclosure for this sale can be found here. 3.10% of the stock is owned by corporate insiders.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Earnings History and Estimates for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply